Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex

Medical Mycology

Volumn 49, Issue 3, 2011, Pages 253-262

  Melo, Analy S ^a   Bizerra, Fernando C ^a   Freymüller, Edna ^b   Arthington Skaggs, Beth A ^c   Colombo, Arnaldo L ^a  

^a Division of Infectious Diseases   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

biofi m production and susceptibility; Candida metapsilosis; Candida orthopsilosis; Candida spp.

Indexed keywords

AMPHOTERICIN B; CRYSTAL VIOLET; FLUCONAZOLE; TETRAZOLIUM;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CELL ASSAY; CELL METABOLISM; CONTROLLED STUDY; FUNGAL METABOLISM; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; NONHUMAN; QUANTITATIVE ANALYSIS; SCANNING ELECTRON MICROSCOPY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; FLUCONAZOLE; GENTIAN VIOLET; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; STAINING AND LABELING; TETRAZOLIUM SALTS;

CANDIDA; CANDIDA ALBICANS; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 79952664196     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.530032     Document Type: Article

References (44)

1. Costerton JW, Stewart PS, Greenberg EP. Bacterial biof lms: a com-mon cause of persistent infections. Science (New York) 1999; 284: 1318-1322. (Pubitemid 29289651)
2. Davey ME, O'Toole GA. Microbial biof lms: from ecology to molec-ular genetics. Microbiol Mol Biol Rev 2000; 64: 847-867. (Pubitemid 32475933)
3. O'Toole G, Kaplan HB, Kolter R. Biof lm formation as microbial development. Ann Rev Microbiol 2000; 54: 49-79.
4. Donlan RM. Biof lm formation: a clinically relevant microbiological process. Clin Infect Dis 2001; 33: 1387-1392. (Pubitemid 32955193)
5. Douglas LJ. Medical importance of biof lms in Candida infections. Rev Iberoam Micol 2002; 19: 139-143. (Pubitemid 35333956)
6. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biof lms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Inf Immun 2002; 70: 878-888. (Pubitemid 34083852)
7. Colombo AL, Guimaraes T, Silva LR, et al. Prospective observational study of candidemia in Sao Paulo, Brazil: incidence rate, epidemiol-ogy, and predictors of mortality. Infect Cont Hosp Epidemiol 2007; 28: 570-576. (Pubitemid 46814547)
8. Kuhn DM, Mikherjee PK, Clark TA, et al. Candida parapsilosis characterization in an outbreak setting. Emerg Inf Dis 2004; 10: 1074-1081. (Pubitemid 38697701)
9. Kumamoto CA. Candida biof lms. Curr Opin Microbiol 2002; 5: 608-611.
10. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biof lms: an update. Eukary Cell 2005; 4: 633-638.
11. Brito LR, Guimaraes T, Nucci M, et al. Clinical and microbiologi-cal aspects of candidemia due to Candida parapsilosis in Brazilian tertiary care hospitals. Med Mycol 2006; 44: 261-266. (Pubitemid 43771932)
12. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001; 33: 1959-1967. (Pubitemid 33152388)
13. Shin JH, Kee SJ, Shin MG, et al. Biof lm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Micro-biol 2002; 40: 1244-1248. (Pubitemid 34279883)
14. Bizerra FC, Nakamura C V, de Poersch C, et al. Characteristics of bio-f lm formation by Candida tropicalis and antifungal resistance. FEMS Yeast Res 2008; 8: 442-450. (Pubitemid 351596147)
15. Colombo AL, Nucci M, Park BJ, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006; 44: 2816-2823. (Pubitemid 44228575)
16. Krcmery V, Jr., Mrazova M, Kunova A, et al. Nosocomial candi-daemias due to species other than Candida albicans in cancer pa-tients. Aetiology, risk factors, and outcome of 45 episodes within 10 years in a single cancer institution. Support Care Cancer 1999; 7: 428-431. (Pubitemid 29489197)
17. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44: 747-751. (Pubitemid 30117972)
18. Branchini ML, Pfaller MA, Rhine-Chalberg J, Frempong T, Isenberg HD. Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis. J Clin Microbiol 1994; 32: 452-456. (Pubitemid 24033911)
19. Krcmery V, Jr., Kovacicova G. Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Slovak Fungaemia study group. Diagnos Microbiol Inf Dis 2000; 36: 7-11. (Pubitemid 30085481)
20. Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005; 43: 284-292. (Pubitemid 40096313)
21. Song JW, Shin JH, Shint DH, et al. Differences in biof lm produc-tion by three genotypes of Candida parapsilosis from clinical sources. Med Mycol 2005; 43: 657-661. (Pubitemid 43084524)
22. Tavanti A, Hensgens LA, Ghelardi E, Campa M, Senesi S. Genotyping of Candida orthopsilosis clinical isolates by amplif cation fragment length polymorphism reveals genetic diversity among independent isolates and strain maintenance within patients. J Clin Microbiol 2007; 45: 1455-1462. (Pubitemid 46762398)
23. Jin Y, Yip HK, Samaranayake YH, Yau JY, Samaranayake LP. Biof lm-forming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodef ciency virus infection. J Clin Microbiol 2003; 41: 2961-2967. (Pubitemid 36842285)
24. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. Standard-ized method for in vitro antifungal susceptibility testing of Can-dida albicans biof lms. Antimicrob Agents Chemother 2001; 45: 2475-2479. (Pubitemid 32801898)
25. Hawser SP, Norris H, Jessup CJ, Ghannoum MA. Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-t etrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J Clin Microbiol 1998; 36: 1450-1452. (Pubitemid 28208050)
26. Ramage G, Bachmann S, Patterson TF, Wickes BL, Lopez-Ribot JL. Investigation of multidrug eff ux pumps in relation to f uconazole resistance in Candida albicans biof lms. J Antimicrob Chemother 2002; 49: 973-980. (Pubitemid 34692891)
27. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biof lms: unique eff cacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-1780. (Pubitemid 34535196)
28. Jabra-Rizk MA, Falkler WA, Meiller TF. Fungal biof lms and drug resistance. Emerg Inf Dis 2004; 10: 14-19. (Pubitemid 38040687)
29. Jain N, Kohli R, Cook E, et al. Biof lm formation by and antifungal susceptibility of Candida isolates from urine. Appl Environ Microbiol 2007; 73: 1697-1703. (Pubitemid 46449049)
30. Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biof lms and planktonic cells of f ve different Candida species. Antimicrob Agents Chemother 2007; 51: 3081-3088. (Pubitemid 350067512)
31. Ramage G, Vandewalle K, Wickes BL, Lopez-Ribot JL. Character-istics of biof lm formation by Candida albicans. Rev Iberoam Micol 2001; 18: 163-170. (Pubitemid 34116636)
32. Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard. 2 edn. Document M27-A2. Wayne, PA: NCSI.
33. Colombo AL, Barchiesi F, McGough DA, Rinaldi MG. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol 1995; 33: 535-540.
34. Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodi-lution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 1995; 39: 2520-2522.
35. Almirante B, Rodriguez D, Park BJ, et al. Epidemiology and predic-tors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-1835.
36. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial blood-stream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317. (Pubitemid 39050477)
37. Adair CG, Gorman SP, Feron BM, et al. Implications of endotracheal tube biof lm for ventilator-associated pneumonia. Int Care Med 1999; 25: 1072-1076. (Pubitemid 29525061)
38. Douglas LJ. Candida biof lms and their role in infection. Trends Microbiol 2003; 11: 30-36. (Pubitemid 36084353)
39. Kuhn DM, Balkis M, Chandra J, Mukherjee PK, Ghannoum MA. Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J Clin Microbiol 2003; 41: 506-508. (Pubitemid 36098635)
40. Chandra J, Kuhn DM, Mukherjee PK, et al. Biof lm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-5394. (Pubitemid 32802612)
41. Ramage G, Wickes BL, Lopez-Ribot JL. Biof lms of Candida albi-cans and their associated resistance to antifungal agents. Am Clin Lab 2001; 20: 42-44.
42. Mah TF, O'Toole GA. Mechanisms of biof lm resistance to antimicro-bial agents. Trends Microbiol 2001; 9: 34-39.
43. Choi HW, Shin JH, Jung SI, et al. Species-specif c differences in the susceptibilities of biof lms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob Agents Chemother 2007; 51: 1520-1523. (Pubitemid 46586842)
44. Katragkou A, Chatzimoschou A, Simitsopoulou M, et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biof lms. Antimicrob Agents Chemother 2008; 52: 357-360.